Assystem: Combined General Meeting of 24 May 2024 - Voting results and dividend for financial year 2023 Combined General Meeting of 24 May 2024Voting results and dividend for financial year 2023 Paris-La Défense, on 24 May 2024, 6.00 p.m (CET) – Assystem S.A. (ISIN: FR0000074148 – ASY), confirms that its Combined General Meeting was held today, at the Centre de conférences Etoile Saint Honoré located at 21-25 rue Balzac, 75008 Paris, chaired by Mr. Dominique Louis, Chairman and CEO. The quorum was 83.25% and the General Meeting approved all resolutions submitted to vote except for ...
The underlying themes discussed at the Forum were the materialisation of the transition of business models, management of emerging ESG risks, adaptation of human capital and the challenges of CSR reporting. Among the 35 companies present, six stood out positively, four warrant caution and three are worth rediscovering from an “improvers” angle. - ...
En toile de fond des thèmes discutés au Forum, il y a la matérialisation de la transition des modèles d’affaires, la gestion de risques ESG émergents, l’adaptation du capital humain, et les enjeux du reporting RSE. Parmi les 35 sociétés présentes, 6 se sont démarquées positivement, 4 méritent la prudence, et 3 sont à redécouvrir sous un angle « improvers ». - ...
>Solid profitability in H1 - With (previously reported) revenues up 12% YoY to € 761m, H1 EBITDA rose 19% YoY to € 277m (vs. € 272m est.), implying a margin of 36.3% (+2bp YoY), benefiting from lower energy costs (-10%), while the rise in opex remained perfectly under control (+9%). By division: i/ ski resorts EBITDA came in at € 254m, up 22% YoY, with a margin of 51% (+3.3bp YoY), benefiting from strong operating leverage with solid momentum on the top line front thi...
>Solide niveau de rentabilité au S1 - Pour un CA (déjà publié), en croissance de 12% y-o-y à 761 M€, l’EBITDA S1 de CDA ressort en hausse de 19% y-o-y à 277 M€ (vs 272 M€e) traduisant une marge de 36.3% (+2 pts y-o-y), bénéficiant de la baisse des dépenses d’énergie (-10%) alors que la hausse des Opex reste parfaitement maîtrisée (+9%). Par division : i/ l’EBITDA des Domaines skiables s’élève à 254 M€ en hausse de 22% y-o-y avec une marge de 51% (+3.3 pts y-o-y) qui a...
Eramet: Successful issue of €500 million sustainability-linked bonds Paris, 23 May 2024, 6:00 p.m. PRESS RELEASE Eramet: Successful issue of €500 million sustainability-linked bonds Eramet announces today the successful issue of sustainability-linked bonds in a principal amount of €500 million and with a 5.5-year maturity and an annual coupon of 6.5 per cent (the “Bonds”). The Bonds have been very well welcomed by a diversified base of institutional investors in France and abroad. The order book, more than 3 times subscribed, reflects the strength of the Group’s fundamentals, its grow...
LYON, France--(BUSINESS WIRE)-- Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC), société biopharmaceutique au stade clinique spécialisée dans la recherche et le développement de solutions thérapeutiques innovantes pour le traitement du diabète et de l’obésité, annonce la tenue de son assemblée générale annuelle (« AGM ») le 13 juin 2024 à 10h30, dans les bureaux du cabinet Jones Day, à l’Hôtel de Talleyrand, 2 rue Saint Florentin, 75001 Paris. L’avis de réunion valant convocation a été publié le lundi 6 mai 2024 au Bulletin des Annonces Légales Obligatoires (« BALO ») et con...
Programme de rachat d'actions propres - Déclaration des transactions sur actions propres réalisées du 13 mai 2024 au 17 mai 2024 Programme de rachat d’actions propres Déclaration des transactions sur actions propres réalisées du 13 mai 2024 au 17 mai 2024 Paris-La Défense, le 21 mai 2024 à 17h35, Conformément à la réglementation relative aux rachats d’actions, Assystem déclare ci-après les transactions sur actions propres réalisées du 13 mai 2024 au 17 mai 2024 : Présentation agrégée Nom de l'émetteurCode Identifiant de l'émetteurJour de la transactionCode identifiant de l'instrument f...
Two Directors at Metrovacesa S.A. sold 143,001 shares at 9.210EUR. The significance rating of the trade was 99/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Launch of an any and all cash tender offer to repurchase its bonds due May 2025 and potential issuance of new sustainability-linked bonds Paris, 21 May 2024, 8:50 a.m. PRESS RELEASE Eramet: Launch of an any and all cash tender offer to repurchase its bonds due May 2025 and potential issuance of new sustainability-linked bonds Eramet (the “Company”) announces today: (i)      the launch of a tender offer to repurchase for cash any and all of its €300 million bonds due May 2025 issued on 21 November 2019 (ISIN: FR0013461274), of which € 293,600,000 are currently outstanding, and ...
Lancement d'une offre de rachat sur l’intégralité des obligations à échéance mai 2025 et projet d’une nouvelle émission d’obligations liées au développement durable (sustainability-linked bonds) Paris, le 21 mai 2024, 8h50 COMMUNIQUE DE PRESSE Eramet : Lancement d'une offre de rachat sur l’intégralité des obligations à échéance mai 2025 et projet d’une nouvelle émission d’obligations liées au développement durable (sustainability-linked bonds) Eramet (la « Société ») annonce aujourd’hui : (i)      le lancement d'une offre de rachat en numéraire portant sur l’intégralité de son...
Edison Investment Research Limited Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis 20-May-2024 / 11:53 GMT/BST The issuer is solely responsible for the content of this announcement. Â London, UK, 20 May 2024 Â Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opport...
BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opportunities. BION’s performance has picked up in recent months, supported by an improvement in the market environment. Its managers are optimistic about the outlook as declines in interest rates, whenever they eventuate, begin to boost investor sentiment towar...
A director at LNA Sante Sa bought 34,000 shares at 20.800EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Growth momentum remains solid, and the publication of Q1 sales bodes well for the future (12.5% organic growth, including 27% for Aerospace). Margins are set to pick up in 2024 (by an estimated 110bp), with the underlying operating profit expected to jump 33%. With good visibility for Aerospace, medium-term potential for Automotive and profitable growth for Medical, we estimate the potential for margin improvement at no less than 500bp in the medium term. We are raising our underlying...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.